Table 1 Baseline characteristics of all 241 CSA patients studied and of the 186 patients that also completed the PSS-10
|  | MHI-5 (n = 241) | PSS-10 (n = 186) |
|---|---|---|
Age, mean (SD) | 44 (9) | 44 (13) |
Female, n (%) | 187 (78) | 147 (79) |
68-tender joint count, median (IQR) | 6 (3–11) | 5 (3–10) |
CRP (mg/L), median (IQR) | 3 (3–5) | 3 (3–5) |
RF positive (≥ 3.5 IU/mL), n (%) | 51 (21) | 37 (20) |
ACPA positive (≥ 7 U/mL), n (%) | 32 (13) | 21 (11) |
Symptom duration in weeks, median (IQR) | 17 (9–31) | 18 (10–31) |